Walder Wyss advised Abingworth and 5AM Venture on Nouscom’s Series B financing round. Nouscom is developing tumor specific oncolytic viruses and patient specific cancer vaccines. The financing round was subscribed by Abingworth and 5AM Venture as well as by existing shareholders.

The Walder Wyss team consisted of Alexander Gutmans (Partner, Corporate, Venture Capital) and Jessica Aeschbach (Associate, Corporate).